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ApoptosisIschemic stroke is an acute vascular event that compromises neuronal viability, and identiﬁcation of the patho-
physiologicalmechanisms is critical for its correctmanagement. Ischemiaproduces increasednitric oxide synthe-
sis to recover blood ﬂow but also induces a free radical burst. Nitric oxide and superoxide anion react to generate
peroxynitrite that nitrates tyrosines.We found that ﬁbrinogen nitrotyrosinationwas detected in plasma after the
initiation of ischemic stroke in human patients. Electron microscopy and protein intrinsic ﬂuorescence showed
that in vitro nitrotyrosination of ﬁbrinogen affected its structure. Thromboelastography showed that initially
ﬁbrinogen nitrotyrosination retarded clot formation but latermade the clotmore resistant toﬁbrinolysis. This re-
sult was independent of any effect on thrombin production. Immunoﬂuorescence analysis of affected human
brain areas also showed that both ﬁbrinogen and nitrotyrosinated ﬁbrinogen spread into the brain parenchyma
after ischemic stroke. Therefore, we assayed the toxicity ofﬁbrinogen and nitrotyrosinated ﬁbrinogen in a human
neuroblastoma cell line. For that purpose we measured the activity of caspase-3, a key enzyme in the apoptotic
pathway, and cell survival. We found that nitrotyrosinated ﬁbrinogen induced higher activation of caspase 3.
Accordingly, cell survival assays showed amore neurotoxic effect of nitrotyrosinated ﬁbrinogen at all concentra-
tions tested. In summary, nitrotyrosinated ﬁbrinogen would be of pathophysiological interest in ischemic stroke
due to both its impact on hemostasis – it impairs thrombolysis, the main target in stroke treatments – and its
neurotoxicity that would contribute to the death of the brain tissue surrounding the infarcted area.
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4 93 316 09 01.1. Introduction
Stroke is a leading cause of death and disability worldwide [1,2]. The
effectiveness of ischemic stroke treatment depends on its rapid and
accurate diagnosis [3]. The currently available treatment target is clot
lysis with recombinant tissue plasminogen activator (rtPA) but carries
a certain risk of bleeding and less than 5% of stroke patients receive
this treatment due to the very narrow therapeutic window for rtPA
(4.5 h after stroke onset) [4].
Ischemic stroke is an acute vascular event that hinders blood supply
to the brain and leads to an ischemic process that affects neurons, glial
cells and vessels. The tissue surrounding the ischemic core lesion is
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sidual blood perfusion [5]. In this scenario, the liberation of nitric oxide
(NO), a molecule with pleiotropic effects in the brain [6], is increased to
favor vasodilatation and blood supply to the compromised brain region
[7], while reperfusion after thrombolysis induces a burst of free radicals
such as the superoxide anion (O2−·) [8,9]. NO reacts with O2− producing
the highly reactive peroxynitrite anion (ONOO−) [10], which, among
other harmful effects, irreversibly nitrates proteins [11,12]. This process,
known as nitrotyrosination, is a post-translational modiﬁcation that
normally leads to a loss of protein function.
Fibrinogen is one of the most abundant plasma proteins. Its main
physiological function is hemostasis as a result of its aggregation to
the ﬁbrin polymers that mediate clot formation. Increased levels of cir-
culating ﬁbrinogen have been identiﬁed as a stroke risk factor [13] as
well as a bad prognosis factor after stroke [14–16]. In the present
work we have evaluated the relevance of ﬁbrinogen nitrotyrosination
in ischemic stroke, with particular emphasis on hemostasis and cell
toxicity.
2. Materials and methods
2.1. Biological material
Human brain sections obtained from autopsies of patients who had
an ischemic stroke were provided by the Servei d'Anatomia Patològica
(Hospital del Mar, Barcelona) corresponding to 4 patients who were
68 ± 34 years old (2 men and 2 women). Human plasma and anti-
coagulant free whole blood samples, provided by the Servei de
Neurologia (Hospital del Mar), were obtained from patients after ische-
mic strokes and from controls. Blood extractionwas carried out approx-
imately 3 h after ischemic stroke. Controls were 53 ± 4 years old (14
men and 9 women); atherothrombotic stroke patients were 70 ±
2 years old (8 men and 9 women); cardioembolic stroke patients
were 78± 2 years old (5men and 9 women); undetermined stroke pa-
tients were 72± 4 years old (2men and 7 women); and lacunar stroke
patients were 67 ± 4 years old (7 men and 5 women). All procedures
were approved by the Ethics Committee of the Institut Municipal
d'Investigacions Mèdiques — Universitat Pompeu Fabra. Subjects gave
informed consent.
Plasmas from rat were obtained from 3-month old Sprague–Dawley
rats. The procedure was approved by the Ethics Committee of the
Universitat de Barcelona.
Human neuroblastoma cell line (SH-SY5Y), supplied by ECACC, were
cultured with Dulbecco's modiﬁed Eagle's medium (DMEM; Invitrogen,
Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (FBS;
Invitrogen, Carlsbad, CA, USA).
2.2. Clot formation
Anti-coagulant free whole blood samples were treated immediately
after extractionwith phosphate-buffered saline (PBS; controls), sodium
nitroprusside (SNP; a NO donor, Sigma, St. Louis, USA) + H2O2 or H2O2
(Sigma, St. Louis, USA). They were allowed to clot for 3 h at 37 °C. Clots
were removed and embedded in optimal cutting temperature com-
pound (Sakura Finetek) medium and frozen to−80 °C. The clots were
analyzed by immunodetection as describedbelow to study the structure
of the ﬁbrin network and the presence of nitrotyrosination.
2.3. Immunodetection
Formalin-ﬁxed parafﬁn-embedded brain sections were cut at 3 μm,
deparafﬁnated at 70 °C for 1 h and washed with decreasing concentra-
tions of ethanol. Antigen retrieval was performed with proteinase K at
40 μg/mL in a 1:1 glycerol and TE buffer solution. Frozen clots were
cut at 5 μm in a cryostat. Immunostaining was performed with 1:200
mouse monoclonal anti-3-nitro-tyrosine (NTyr; Cayman Chemical,Michigan, USA) antibody (Ab) or 1:200 rabbit polyclonal anti-human ﬁ-
brinogen (Dako, California, USA) Ab for 2 h at room temperature (RT)
followed by 1:1000 Alexa555-bound anti-mouse or 1:1000 Alexa488-
bound anti-rabbit as secondary Abs (Dako, California, USA) overnight
(o.n.) at 4 °C. Sections were stained with TO-PRO to identify the nuclei
andmounted withMowiol. Images were taken with a Leica TCS SP con-
focal microscope and analyzed with Leica confocal software (Leica).
SH-SY5Y cells (4 × 104 cells/well) were seeded on 1.5% gelatin-
coated 12 mm coverslips. Cells were treated for 45 min with PBS
(controls), 5 μg/μL ﬁbrinogen (Sigma, St. Louis, USA) or 5 μg/μL nitro-
ﬁbrinogen prepared by pre-incubating ﬁbrinogen with 100 μM 3-
morpholinosydnonimine hydrochloride (SIN-1; Sigma, St. Louis, USA),
an ONOO– donor. They were ﬁxed after 45 min (ﬁbrinogen challenge)
and incubated for 2 h at RT with 1:500 rabbit anti-cleaved caspase-3
(Asp175) Ab (Cell Signaling, Beverly, USA) followed by 1:500 Alexa
Fluor 488 goat anti-rabbit polyclonal Ab for 1 h at RT. Cells were stained
with TO-PRO to identify the nuclei and mounted with Mowiol. Images
were taken with a Leica TCS SP confocal microscope and analyzed
with Leica confocal software (Leica).2.4. Focal cerebral ischemia in rats
Focal cerebral ischemia was produced by transient intraluminal
occlusion of the middle cerebral artery (MCA) in rats, as previously re-
ported [17]. Plasma (500 μL) was extracted from the rats after 3, 6, 12,
and 24 h of MCA occlusion. The procedure was approved by the Ethics
Committee of the Universitat de Barcelona (CEEA-273/09).2.5. Fibrinogen immunoprecipitation
Human and rat plasma samples (350 μL) were incubated with
5 μg of anti-human ﬁbrinogen polyclonal Ab or to 5 μg of anti-rat ﬁ-
brinogen polyclonal Ab (Accu-Specs, Westbury, NY, USA). Samples
were shaken overnight at 4 °C. Following addition of 20 μg of protein
G-sepharose (Sigma, St. Louis, USA), samples were shaken for 2 h at
25 °C, centrifuged at 10,000 rpm for 10 min and washed 3 times with
PBS.2.6. Quantiﬁcation of nitrotyrosination
Immunoprecipitated ﬁbrinogen was used at a ﬁnal volume of
100 μL. NTyr was determined spectrophotometrically by the absor-
bance measurement at 415 nm (pH N 9) [18]. A calibration curve
using serial dilutions of free NTyr (Sigma, St. Louis, USA) was used
to quantify nitrotyrosination expressed as NTyr μg/μL or mol of
NTyr/mol of Fib.2.7. Fibrinogen conformational state analysis by intrinsic ﬂuorescence
measurement
Intrinsic protein ﬂuorescence emission is mainly due to tryptophan
residues, which have a wavelength of maximum absorption of 280 nm
and an emission peak ranging from 300 to 350 nm. Therefore the shift
in protein ﬂuorescence can be used to study the changes in protein
conformational states [19]. Freeze-dried human ﬁbrinogen was directly
solubilized at 1 mg/mL in TBS (50 mM Tris base, 150 mM sodium
chloride; pH 7.4). Fibrinogen was then incubated in the presence of
12 mM CaCl2, with or without 100 μM SIN-1 at 37 °C for 24 h in the
dark. Intrinsic ﬂuorescence measurements of these mixtures were
determined in a Shimadzu spectroﬂuorophotometer (RF-5301).
Samples were excited at 280 nm and ﬂuorescence emission reading
was recorded between 300 and 400 nm.
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Samples of 5 μL of ﬁbrinogen (1mg/mL) incubated in the absence or
presence of 100 μM SIN-1 were applied to carbon-coated Formvar grids
(Sigma, St. Louis, USA). Samples were stained with 5 μL of 0.5% phos-
photungstic acid solution (Sigma, St. Louis, USA). Samples were exam-
ined under a JEOL 1200 EX II electron microscope at 80 kV.
2.9. Thromboelastometry studies
Whole blood from control donors was incubated with 10 mM SNP
and 50 μM H2O2, to induce a superoxide anion production, or only
with 50 μMH2O2, a control for oxidative stress, at 37 °C for 1 h and eval-
uated using the ROTEM Thromboelastometry Analyzer (Pentapharm
GmbH, Munich, Germany). This technique was performed according
to the manufacturer's instructions. TEM studies focused on analysis of
the ExTEM and FibTEM tests. Brieﬂy, ExTEM evaluates viscoelastic
changes in ﬁbrin polymerization and platelet contractile resistance in-
duced through the activation of the extrinsic coagulation pathway by
tissue factor. The FibTEM test is also based on activation of the extrinsic
coagulation pathway, but includes cytochalasin that inhibits platelet cy-
toskeletal contraction. Viscoelastic properties of clots formed with the
ExTEM are contributed by polymerizing ﬁbrin and platelets, whereas
those formed with the FibTEM are mainly contributed by ﬁbrin. This
technique provides information through different parameters. We
assessed four variables. The clotting time (CT), deﬁned as the time
elapsed from the measurement start until the amplitude of the forming
clot reaches 2 mm. The clot formation time (CFT) is the time from the
start of clot formation until this clot reaches 20 mm of amplitude. CT
and CFT indicate the dynamics of clot formation. The maximum clot
ﬁrmness (MCF) was evaluated as a measure of clot ﬁrmness. The clot
amplitude gives information about clot strength and stability, which is
largely dependent on ﬁbrinogen and platelets. The maximum lysis
(ML) describes the degree of ﬁbrinolysis relative to MCF achieved dur-
ing the measurement (% clot ﬁrmness lost). Time 0 is based on shear.
All analyses were carried out for 1 h.
2.10. Coagulation pathway study in samples from stroke patients
Blood samples from stroke patients were collected in tubes with so-
dium citrate. The intrinsic pathway was activated by adding calcium.
Time was measured until clot formation (Partial Thrombin Time; PTT)
and expressed in seconds. The extrinsic pathway was activated by
adding tissue factor (factor III) to isolated plasma. Time was measured
until clot formation (Prothrombin Time; PT) and expressed as the Inter-
national Normalized Ratio multiplied by 100.
2.11. Cell viability assays
SH-SY5Y cells (104 cells/well) were treated with increasing concen-
trations of ﬁbrinogen or nitro-ﬁbrinogen for 24 h. Cell viability was
measured by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) reduction method and expressed as a percentage of
control [11].
2.12. Statistics
All data are expressed asmean±SEMof n independent samples/ex-
periments analyzed in duplicate or triplicate. Statistical analysis was
performed with paired Student's t-test for two comparisons and one-
way ANOVA followed by LSD post-hoc analysis for multiple compari-
sons. p b 0.05 was considered signiﬁcantly different from the reference
value. Correlation analysis was carried out with the Pearson Correlation
Test.3. Results
3.1. Ischemic conditions induce nitro-oxidative stress and ﬁbrinogen
nitrotyrosination
Human brain slices obtained from autopsies of stroke patients
were analyzed for the presence of nitro-oxidative stress. A diffuse
nitrotyrosination staining (Fig. S1A), secondary to peroxynitrite
anion (ONOO−) production, was detected in the infarcted area (pre-
viously identiﬁed post-mortem at the Hospital del Mar Pathology
Department). Unaffected areas located in the same brain slice
showed no signs of nitrotyrosination. The presence of advanced
glycation end-products (AGEs), indicative of radical oxygen species
production [20,21], was also detected in infarcted areas but absent
in unaffected regions (Fig. S1B). Similarly, human neuroblastoma
cells (SH-SY5Y) subjected to oxygen and glucose deprivation
(OGD) for 1 h followed by reoxygenation and immersion in
glucose-containing medium (mimicking the ischemia–reperfusion
process that occurs during stroke) [22], showed higher levels of pro-
tein nitrotyrosination (Fig. S1C), and oxidative stress, as revealed by
AGEs (Fig. S1D), than control cells. Brain ischemic conditions trigger
nitro-oxidative stress and the generation of peroxynitrite [23]. Ische-
mic stroke also alters the permeability of the blood brain barrier en-
abling the extravasation of plasmatic proteins into the penumbra
area of the infarcted brain parenchyma [24,25] but, is it possible for
the peroxynitrite produced during the ischemic conditions of a
stroke to spread its harmful effects to plasma proteins? Peroxynitrite
is a highly reactive compound and under physiological conditions
has a half-life of 1–2 s and an action radius of 100 μm [10]. These
properties make it possible after an ischemic process for the
peroxynitrite burst to reach the lumen of blood vessels affecting
the circulating plasmatic proteins.
We focused our attention on ﬁbrinogen, which is the third most
abundant protein in plasma and plays a key role in hemostasis, a critical
physiological process in stroke progression. Using an anti-ﬁbrinogen
antibody to analyze the brain parenchyma, we found an intense signal
corresponding to ﬁbrinogen extravasation that partially colocalized
with the nitrotyrosination staining in the parenchyma from an ischemic
stroke patient (Fig. 1A).
We then analyzed nitrotyrosination of plasma ﬁbrinogen in both an
animal model of brain ischemia, and in stroke patients. Transient occlu-
sion ofMCA in rats produced an infarction affecting the ipsilateral cortex
and striatum. The mean infarct volume was 315.9 ± 64.4 mm3
(mean± SEM), measured as previously described [26]. Plasma samples
were extracted from rats before induction of ischemia (0 h) and at 3, 6,
12, and 24 h after MCA occlusion. A large increase in plasmatic
nitrotyrosinated ﬁbrinogen (NTyr) was detected with a peak at 3 h
(Fig. 1B). Elevated levels of nitrotyrosination were detected up to
24 h after MCA occlusion demonstrating that nitrotyrosination of ﬁ-
brinogen was maintained at high levels as a direct consequence of
brain ischemia.
The presence of nitrotyrosinated ﬁbrinogen was also measured in
human plasma samples approximately 3 h after suffering different
types of ischemic stroke: atherothrombotic, cardioembolic, undeter-
mined and lacunar. The levels of nitrotyrosinated ﬁbrinogen
obtained from patients suffering from any type of ischemic stroke
were signiﬁcantly higher than those detected in healthy controls
(p b 0.01 for atherothrombotic stroke; p b 0.05 for cardioembolic
and undetermined strokes; and p b 0.0005 for lacunar stroke;
Fig. 1C).
Nitrotyrosination of plasma proteins from healthy donors was also
evaluated in vitro. A wide range of proteins with different molecular
sizes can be extensively nitrotyrosinated by the peroxynitrite donor
SIN-1 in a dose-dependent manner (Fig. S2A). The nitrotyrosination
was prevented by the natural antioxidant reduced glutathione (GSH)
(Fig. S2B).
Fig. 1. Fibrinogen is nitrotyrosinated after brain ischemia. (A)Humanbrain parenchyma from a patient suffering an ischemic strokewas analyzed for nitrotyrosination and ﬁbrinogenwith
anti-ﬁbrinogen and anti-nitrotyrosination antibodies. Bars are 100 μm. (B) Rats were subjected toMCA occlusion and plasma sampleswere obtained at 0, 3, 6, 12, and 24 h post-ischemia.
Fibrinogen was immunoprecipitated and its nitrotyrosination measured. Data are expressed as themean± SEM. The number of animal samples analyzed at each time is indicated in pa-
rentheses. Samples were analyzed in duplicate. *p b 0.05; **p b 0.001 by one-way ANOVA followed by LSD post-hoc analysis. (C) Quantiﬁcation of plasma ﬁbrinogen nitrotyrosination in
controls and atherothrombotic, cardioembolic, undetermined and lacunar stroke patients. Sampleswere extracted around 3 h after the stroke episode. Data aremean± SEM. The number
of patients is indicated in parentheses. *p b 0.05; **p b 0.01; ***p b 0.0005 by one-way ANOVA followed by LSD post-hoc analysis.
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Considering the relevance of ﬁbrinogen in stroke prognosis [14–16]
we studied the functional consequences of its nitrotyrosination. Analy-
sis of the shift in intrinsic protein ﬂuorescence, a technique used to de-
tect conformational changes in proteins [19], revealed a reduction in the
ﬂuorescence emission of ﬁbrinogen treated with the peroxynitrite
donor SIN-1, indicating structural alterations in nitrotyrosinated ﬁbrin-
ogen (Fig. 2A). This ﬁndingwas conﬁrmed by electronmicroscopy stud-
ies showing that nitrotyrosinated ﬁbrinogen formed globular structures
that were clearly different from the needle-shaped geometry observed
in non-treated ﬁbrinogen (Fig. 2B).
In order to analyze the impact of ﬁbrinogen nitrotyrosination on
blood hemostasis, we incubated human blood samples from healthy in-
dividuals with 10 mM SNP, a nitric oxide donor, and 50 μM H2O2 as a
source of free radicals. This treatmentmimics the nitro-oxidative condi-
tion that leads to the peroxynitrite burst in the ischemic brain. Both
compounds (SNP and H2O2) react to form peroxynitrite and the conse-
quent nitrotyrosination was observed in the treated clot samples
(Fig. 3C) but not in the control clots (Fig. 3A) or those treated with
H2O2 alone (Fig. 3E). Nitrative stress also affected the coagulation pro-
cess (see Fig. S3 for a diagram of the clot formation), as assessed by
thromboelastometric analysis (Table 1, Figs. 3B, D and F, Fig. S4). The
speciﬁc contribution of nitro-ﬁbrinogen to clotting was addressed
using the FibTEM test (Table 1), which represents only the ﬁbrin com-
ponent of the clot because platelets are inhibited. This test is used for
the detection of ﬁbrinogen deﬁciency or ﬁbrin polymerization disor-
ders. The clotting time (CT) measures the ﬁbrin formation time as a re-
sult of the proteolytic action of thrombin on ﬁbrinogen (see Fig. S3),
which is the initial step of the hemostatic response. The FibTEM analysisshowed a signiﬁcantly higher CT when ﬁbrinogen was nitrotyrosinated
(p b 0.05), but no differenceswere observedwhenH2O2was used alone,
indicating that only nitrotyrosination slowed down ﬁbrin formation
(Table 1). These results could be due to a global nitrotyrosination of
the proteins and factors that act in the coagulation cascade.
The coagulation cascade is composed of the intrinsic and the extrin-
sic pathways. Both pathways involve a high number of proteins directed
to produce the cleavage of prothrombin into the active thrombin
(Fig. S3). Therefore we studied the impact of nitro-oxidative stress in
the proteins that participate in the coagulation cascade by the study of
PTT, which measures the intrinsic pathway, and PT, which measures
the extrinsic pathway. Both techniques provide information on the
physiological thrombin production. We discarded any signiﬁcant
effect of nitro-oxidative stress in the coagulation cascade since no corre-
lation was found between these two pathways and the levels of
nitrotyrosinated ﬁbrinogen in stroke patients (Fig. 4). In this case
nitrotyrosinated ﬁbrinogen works just as a parameter of general
plasmatic protein nitrotyrosination. The lack of correlation between
nitro-oxidative stress and changes in the coagulation cascade was cor-
roborated when plasma samples were nitrotyrosinated in vitro (Fig. S5).
Considering that nitrotyrosination might affect various proteins be-
sides ﬁbrinogen (Fig. S3), ExTEM was used to analyze the effect of
nitrotyrosination on the clotting process in toto (Table 1; Fig. 3). The
ExTEM test mildly activates hemostasis via the physiological activator
tissue factor. The result is inﬂuenced by extrinsic coagulation factors,
platelets and ﬁbrinogen. A signiﬁcantly higher CT was obtained when
nitrotyrosination was induced with the NO donor SNP plus H2O2
(Table 1; p b 0.01), conﬁrming the observation that there is a decrease
in the rate of ﬁbrin formation under nitrative conditions. Clot formation
time (CFT)measures the interaction of theﬁbrin networkwith platelets,
Fig. 2.Nitrotyrosination induces structural changes inﬁbrinogen. (A) Changes in the intrinsicﬂuorescent emission signal of nitrotyrosinated ﬁbrinogen. Humanﬁbrinogen (1mg/mL)was
incubatedwith or without 100 μMSIN-1. Intrinsic ﬂuorescencewasmeasured (Excitation: 280 nm; Emission: 300–400 nm). Themaximumdifferences were recorded at 340 nm and the
results are shown as bars representing themean± SEMof 4 independent experiments performed in triplicate. *p b 0.001 by paired Student's t-test. (B) Electronmicrographs of ﬁbrinogen
incubated with or without 100 μM SIN-1 at 37 °C for 24 h in the dark. Samples were negatively-stained and analyzed by transmission electron microscopy. Bars represent 200 nm.
Fig. 3. Nitrotyrosination affects coagulation. Untreated human blood samples (A, B), blood samples treated with 10 mM SNP + 50 μM H2O2 (C, D) or treated with 50 μM H2O2 alone
(E, F) were stained with anti-ﬁbrinogen (left panels) and anti-NTyr (middle panels) antibodies and analyzed by confocal microscopy. B, D and F show the result of the
thromboelastography analysis of the clots described in A, C and E. Thromboelastograms show the clotting time (red color) and ﬁrmness (blue color) of the clot before plasmin starts to
degrade it, measuring between 0 at the initiation of the clotting to 100 mm, assumed as the maximum theoretical ﬁrmness. Bars are 100 μm.
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Table 1
Thromboelastometric analysis.
Baseline SNP + H202 H202
FibTEM
CT [s] 52.7 ± 0.67 63.3 ± 3.4⁎ 48.5 ± 2.5
ExTEM
CT [s]
CFT [s]
MCF [mm]
ML [%]
57.0 ± 3.1
91.0 ± 5.3
64 ± 2.3
8.3 ± 1.8
78.7 ± 3.3⁎⁎
151.3 ± 2.6⁎⁎⁎
50.0 ± 4.0⁎
1.3 ± 0.9⁎
61.0 ± 3.3
97.5 ± 9.5
62.5 ± 4.5
9.0 ± 2.0
Coagulation study performed in whole blood from 3 healthy controls. Data correspond to
clotting time (CT), clot formation time (CFT), maximum clot ﬁrmness (MCF) and maxi-
mum lysis (ML) expressed as mean ± SEM. Data were evaluated statistically using one-
way ANOVA followed by LSD post-hoc analysis.
⁎ p b 0.05.
⁎⁎ p b 0.01.
⁎⁎⁎ p b 0.001.
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higher when nitrotyrosination was induced (Table 1; p b 0.001),
indicating that protein nitrotyrosination impairs coagulation and also
platelet–platelet and platelet–ﬁbrinogen interaction, which ﬁts with
the data obtained in vitro when platelet aggregation was studied
(Fig. S6). Maximum clot ﬁrmness (MCF) measures the ﬁrmness of the
mature clot before plasmin starts to degrade it, the ﬁnal step in the
hemostatic response. A decreased MCF compared to controls was
obtained when nitrotyrosination was induced (Table 1; p b 0.05).
Thromboelastograms also show a decrease in the width of
nitrotyrosinated clots (Fig. 3D), an effect directly related to the lowﬁrm-
ness of these clots. Analysis of the persistence of the clots over time
allowed quantiﬁcation of the maximum lysis (ML) by measuring
ﬁbrinolysis on MCF. The results showed that nitrotyrosination inhibitsFig. 4. Study of the effect of ischemic stroke on the coagulation cascade. (A) Partial throm-
boplastin time (PTT) measures the activity of the intrinsic coagulation cascade. The graph
shows the correlation study between PTT and nitro-ﬁbrinogen in stroke patients (n=25).
(B) Prothrombin time (PT) measures the extrinsic coagulation pathway. The graph shows
the correlation study between PT and nitro-ﬁbrinogen in stroke patients (n = 29).ﬁbrinolysis (Table 1; p b 0.05)making the clots more stable for a longer
time. None of the hemostasis steps analyzedwere affected by the oxida-
tive conditions induced with H2O2 alone. On the other hand, nitro-
oxidative stressmay affect other factors that also participate in clot lysis.
3.3. Neuronal effects of ﬁbrinogen nitrotyrosination
Because ﬁbrinogen deposition in the brain of mice seriously dam-
ages neurons [27], an assessment was made of the effect of soluble
ﬁbrinogen and nitro-ﬁbrinogen on a human neuroblastoma cell line.
Following exposure of the cells to both types of ﬁbrinogen, measure-
mentsweremade of the activation of caspase-3, a key enzyme in the in-
tracellular apoptotic pathway. It was found that at pathophysiological
concentrations, both types of ﬁbrinogen activate caspase-3 after
45 min of treatment (Figs. 5A–B), being nitro-ﬁbrinogen a more potent
caspase-3 activator than unmodiﬁed ﬁbrinogen (p b 0.05). These data
correlated with viability assays carried out on neuroblastoma cells
(Fig. 5C). Nitro-ﬁbrinogen was neurotoxic at all concentrations tested
and always more toxic than normal ﬁbrinogen, which was toxic only
at 5 and 10 μg/μL.
4. Discussion
In an ischemic stroke the tissue responds with a cascade of events
that aims to protect the damaged brain, e.g. increased NO production
to vasodilate andmaintain blood perfusion [28]. Moreover, ischemia re-
sults in mitochondrial dysfunction, which in turn leads to a burst in free
radical production [8], and the generation of peroxynitrite [29]. Subse-
quent protein nitrotyrosination, which participates in massive tissue
parenchyma damage, will be largely responsible for cell death.
Our ﬁndings suggest that the toxic effects of peroxynitrite are not
merely conﬁned to the brain tissue affected by the disruption in blood
supply, but can target circulating plasma proteins as well. We detected
circulating ﬁbrinogen nitrotyrosination as early as 3 h after the ﬁrst
stroke symptoms. Therefore, the proﬁle of ﬁbrinogen nitrotyrosination
after brain ischemia seems tomirror the pathophysiological events tak-
ing place at the ischemic focus. All subtypes of ischemic stroke
(atherothrombotic, cardioembolic, undetermined, and lacunar) show
signiﬁcantly higher values of ﬁbrinogen nitrotyrosination, suggesting
that regardless of the causes of the ischemic stroke, all of them share a
common mechanism that leads to peroxynitrite production.
Absolute increases in ﬁbrinogen levels have been reported in
stroke patients, probably reﬂecting ﬁbrinogen's up-regulation as an
acute-phase reactive protein [30], and has been related to both
prognosis and risk factors of stroke [14,13]. Our data suggest that ﬁbrin-
ogen nitrotyrosination induces impairment of the cleavage of
nitrotyrosinated ﬁbrinogen by thrombin due to the structural changes
of the molecule without detectable changes in thrombin activity per
se. This impairment also affects the assembly of the ﬁbrinopeptides to
form ﬁbrin and the ﬁbrin–ﬁbrin interaction, since the whole tyrosines
present in ﬁbrinogen are in the ﬁbrinopeptides. Moreover its binding
to platelet is also dramatically affected.
Therefore ﬁbrinogen nitrotyrosination slows down coagulation and
makes the clots more resistant to ﬁbrinolysis. This process could be a
protective response tomodulate coagulation in away that allows partial
perfusion at the early stages of the hemostasis response but stabilizes
the clots at longer times. Our observation on the impact of ﬁbrinogen
nitrotyrosination on hemostasismay also apply to other ischemic condi-
tions presenting increased nitrotyrosinated ﬁbrinogen such as myocar-
dial infarct due to coronary artery disease [31]. Thus, nitro-ﬁbrinogen
can be seen as a rapid unspeciﬁc biomarker of acute ischemic processes
that may facilitate a rapid and accurate diagnosis of ischemic stroke,
reducing themortality, neurological deﬁcits and systemic damage asso-
ciated with late diagnosis [32–34].
We found that plasma nitrotyrosination can be prevented with the
antioxidant GSH, probably due its scavenging effect, avoiding
Fig. 5. Fibrinogen and nitro-ﬁbrinogen induce neurotoxicity. (A) Human neuroblastoma cells were treated with 5 μg/μL ﬁbrinogen and nitro-ﬁbrinogen. Caspase-3 activation was studied
45min after treatment. Bars are 50 μm. (B) Quantiﬁcation of caspase-3 activation by ﬁbrinogen and nitro-ﬁbrinogen. Data are themean± SEMof 4 independent experiments analyzed by
one-way ANOVA followed by LSD post-hoc analysis. (a) p b 0.05, (aa) p b 0.005 in comparison to the controls; *p b 0.05 in comparison to ﬁbrinogen data. (C) Human neuroblastoma cells
were treated with increasing concentrations of ﬁbrinogen and nitro-ﬁbrinogen. Cell viability was measured by MTT reduction. Data are the mean ± SEM of 6 independent experiments
performed in triplicate and analyzed by one-wayANOVA followedby LSDpost-hoc analysis. (a) p b 0.05, (aa) p b 0.005 in comparison to the controls; *p b 0.05 in comparison to ﬁbrinogen
data.
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aging constitutes a major risk factor for stroke [35–37], and polymor-
phisms in some enzymes related to GSH biosynthesis have been related
to a higher risk of stroke [38–40]. Therefore, it is plausible to think that
circulatingGSH avoids protein nitrotyrosination in basal conditions, and
that this protective mechanismmight be compromised in subjects that
are susceptible of suffering a stroke.
Fibrinogen is also a known pro-inﬂammatory agent in the brain [41].
The increased permeability of the blood brain barrier during ischemic
stroke [42,43] allows extravasation of different plasmatic proteins into
the brain parenchyma. Our ﬁndings demonstrate the ﬁbrinogen-
dependent activation of proapoptotic caspase-3 and neuronal death,
an effect enhanced by ﬁbrinogen nitrotyrosination. Together, these ex-
periments suggest that ﬁbrinogen, and especially nitro-ﬁbrinogen,
play a relevant role in the progression of brain tissue damage in the pen-
umbra area, determining the magnitude of the ﬁnal injury.
5. Conclusions
In summary, nitro-ﬁbrinogen may be seen as a Janus molecule that
participates in processes that are critical to themanagement of ischemic
stroke. At early stages nitro-ﬁbrinogen has a protective role, delaying
clot formation, but in the long term it becomes harmful due to the
production of ﬁbrinolysis resistant clots and the induction of neuronal
damage. Altogether, the present ﬁndings indicate that nitro-ﬁbrinogen
is a key molecule in the pathophysiology of ischemic stroke and it
would be plausible to consider it as a novel therapeutic target.
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